• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Anal Bioanal Chem . Targeted and untargeted cross-sectional study for sex-specific identification of plasma biomarkers of COVID-19 severity

tetano

Editor, Senior Moderator
Anal Bioanal Chem


. 2024 Dec 23.
doi: 10.1007/s00216-024-05706-x. Online ahead of print. Targeted and untargeted cross-sectional study for sex-specific identification of plasma biomarkers of COVID-19 severity

Lia Olivares-Caro[SUP] 1 [/SUP], Daniela Nova-Baza[SUP] 2 [/SUP], Felipe Sanhueza[SUP] 3 [/SUP], Hector Contreras[SUP] 1 [/SUP], Barbara Alarcón[SUP] 1 2 [/SUP], Pedro Alarcon-Zapata[SUP] 1 [/SUP], Daniela Mennickent[SUP] 2 [/SUP], Daniel Duran[SUP] 1 [/SUP], Luis Bustamante[SUP] 2 [/SUP], Andy J Perez[SUP] 2 [/SUP], Daniel Enos[SUP] 3 4 [/SUP], Carola Vergara[SUP] 2 [/SUP], Claudia Mardones[SUP] 5 [/SUP]



Affiliations
Abstract

Coronavirus disease 2019 is a highly contagious respiratory illness caused by the coronavirus SARS-CoV-2. Symptoms can range from mild to severe and typically appear 2-14 days after virus exposure. While vaccination has significantly reduced the incidence of severe complications, strategies for the identification of new biomarkers to assess disease severity remains a critical area of research. Severity biomarkers are essential for personalizing treatment strategies and improving patient outcomes. This study aimed to identify sex-specific biomarkers for COVID-19 severity in a Chilean population (n = 123 female, n = 115 male), categorized as control, mild, moderate, or severe. Data were collected using clinical biochemistry parameters and mass spectrometry-based metabolomics and lipidomics to detect alterations in plasma cytokines, metabolites, and lipid profiles related to disease severity. Principal component analysis (PCA) and orthogonal partial least squares discriminant analysis (OPLS-DA) were performed to select significant characteristic features for each group. The results revealed distinct biomarkers for males and females. In males, COVID-19 severity of was associated with inflammation parameters, triglycerides content, and phospholipids profiles. For females, liver damage parameters, triglycerides content, cholesterol derivatives, and phosphatidylcholine were identified as severity biomarkers. For both sexes, most of the biomarker combinations evaluated got areas under the ROC curve greater than 0.8 and low prediction errors. These findings suggest that sex-specific biomarkers can help differentiate the levels of COVID-19 severity, potentially aiding in the development of tailored treatment approaches.

Keywords: Clinical biochemistry; SARS-CoV-2; Severity; Sex-specific; Untargeted metabolomics.

 
Back
Top Bottom